WallStSmart

Ideaya Biosciences Inc (IDYA)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 177% more annual revenue ($606.42M vs $218.71M). INSM leads profitability with a -2.1% profit margin vs -52.0%. INSM earns a higher WallStSmart Score of 39/100 (F).

IDYA

Avoid

35

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 9.0
Piotroski: 4/9Altman Z: 6.56

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IDYA4 strengths · Avg: 9.5/10
Revenue GrowthGrowth
55.4%10/10

Revenue surging 55.4% year-over-year

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
6.5610/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

IDYA4 concerns · Avg: 2.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-10.9%2/10

ROE of -10.9% — below average capital efficiency

Free Cash FlowQuality
$-90.83M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-52.0%1/10

Currently unprofitable

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : IDYA

The strongest argument for IDYA centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 55.4% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : IDYA

The primary concerns for IDYA are EPS Growth, Return on Equity, Free Cash Flow.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

IDYA profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

IDYA is growing revenue faster at 55.4% — sustainability is the question.

IDYA generates stronger free cash flow (-91M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 35/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ideaya Biosciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California.

Visit Website →

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?